Taysha Gene Therapies Inc (NASDAQ:TSHA) has a beta value of 0.94 and has seen 0.85 million shares traded in the recent trading session. The company, currently valued at $703.52M, closed the recent trade at $2.69 per share which meant it gained $0.05 on the day or 1.89% during that session. The TSHA stock price is -23.05% off its 52-week high price of $3.31 and 60.97% above the 52-week low of $1.05. If we look at the company’s 10-day average daily trading volume, we find that it stood at 2.2 million shares traded. The 3-month trading volume is 3.76 million shares.
The consensus among analysts is that Taysha Gene Therapies Inc (TSHA) is Buy stock at the moment, with a recommendation rating of 1.08. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 1 out of 8 have rated it as a Hold, with 7 advising it as a Buy. 0 have rated the stock as Underweight.
Taysha Gene Therapies Inc (NASDAQ:TSHA) trade information
Sporting 1.89% in the green today, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the TSHA stock price touched $2.69 or saw a rise of 1.1%. Year-to-date, Taysha Gene Therapies Inc shares have moved 19.03%, while the 5-day performance has seen it change 14.96%. Over the past 30 days, the shares of Taysha Gene Therapies Inc (NASDAQ:TSHA) have changed 0.75%. Short interest in the company has seen 33.27 million shares shorted with days to cover at 6.71.
Wall Street analysts have a consensus price target for the stock at $8.5, which means that the shares’ value could jump 68.35% from the levels at last check today.. The projected low price target is $5.0 while the price target rests at a high of $44.0. In that case, then, we find that the latest price level in today’s session is -1535.69% off the targeted high while a plunge would see the stock gain -85.87% from the levels at last check today..
Taysha Gene Therapies Inc (TSHA) estimates and forecasts
The company’s shares have gained 39.38% over the past 6 months.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -63.99% over the past 5 years. Earnings growth for 2025 is a modest 11.63% while over the next 5 years, the company’s earnings are expected to increase by 11.06%.
TSHA Dividends
Taysha Gene Therapies Inc is expected to release its next earnings report on 2025-May-15 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Taysha Gene Therapies Inc (NASDAQ:TSHA)’s Major holders
Insiders own 12.11% of the company shares, while shares held by institutions stand at 67.23% with a share float percentage of 76.49%. Investors are also buoyed by the number of investors in a company, with Taysha Gene Therapies Inc having a total of 165.0 institutions that hold shares in the company. The top two institutional holders are FMR LLC with over 21.21 million shares worth more than $47.51 million. As of 2024-06-30, FMR LLC held 9.1103% of shares outstanding.
The other major institutional holder is RTW INVESTMENTS, LP, with the holding of over 18.8 million shares as of 2024-06-30. The firm’s total holdings are worth over $42.11 million and represent 8.075% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF . As of Mar 31, 2025 , the former fund manager holds about 2.26% shares in the company for having 4.85 shares of worth $13.02 million while later fund manager owns 4.46 shares of worth $11.97 million as of May 31, 2025 , which makes it owner of about 2.08% of company’s outstanding stock.
